Recent chatter on X about Edwards Lifesciences (EW) has centered on the company’s strong Q2 financial performance, which exceeded expectations with adjusted earnings per share of $0.67 against a consensus of $0.62, and revenue of $1.53 billion compared to the anticipated $1.49 billion. Many users have highlighted the company’s raised full-year sales growth guidance to 9-10%, signaling confidence in sustained momentum. The buzz reflects a renewed interest in the stock’s trajectory following these results.
Additionally, discussions have noted positive analyst moves, such as a price target increase by a major firm from $78 to $79, further fueling optimism among some investors. There’s a sense of intrigue around how the stock might perform in the near term, especially with insider transactions also making waves in the conversation. The tone on X suggests that many see this as a pivotal moment for the medical device giant.
Note: This discussion summary was generated from an AI condensation of post data.
Edwards Lifesciences Congressional Stock Trading
Members of Congress have traded $EW stock 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $EW stock by members of Congress over the last 6 months:
- REPRESENTATIVE JEFFERSON SHREVE has traded it 2 times. They made 1 purchase worth up to $50,000 on 04/07 and 1 sale worth up to $100,000 on 05/12.
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 04/08.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Edwards Lifesciences Insider Trading Activity
Edwards Lifesciences insiders have traded $EW stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.
Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:
- SCOTT B. ULLEM (CVP, Chief Financial Officer) has made 0 purchases and 5 sales selling 45,000 shares for an estimated $3,282,900.
- BERNARD J ZOVIGHIAN (CEO) has made 0 purchases and 4 sales selling 29,210 shares for an estimated $2,194,261.
- DONALD E JR BOBO (CVP,Strategy/Corp Development) has made 0 purchases and 5 sales selling 28,070 shares for an estimated $2,000,094.
- LARRY L WOOD (Global President TAVR & Surg) sold 8,950 shares for an estimated $673,268
- DANIEL J. LIPPIS (CVP, JAPAC) has made 0 purchases and 5 sales selling 5,644 shares for an estimated $438,605.
- STEVEN R LORANGER sold 5,739 shares for an estimated $438,575
- HEISZ LESLIE STONE sold 5,739 shares for an estimated $435,370
- DAVEEN CHOPRA (CVP, TMTT) sold 1,500 shares for an estimated $112,612
- WAYNE MARKOWITZ (GM & SVP, Surgical) sold 268 shares for an estimated $20,120
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Edwards Lifesciences Hedge Fund Activity
We have seen 488 institutional investors add shares of Edwards Lifesciences stock to their portfolio, and 627 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 7,110,139 shares (+47.9%) to their portfolio in Q1 2025, for an estimated $515,342,874
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 4,247,627 shares (+5595.5%) to their portfolio in Q1 2025, for an estimated $307,868,004
- WELLINGTON MANAGEMENT GROUP LLP removed 4,076,089 shares (-12.3%) from their portfolio in Q1 2025, for an estimated $295,434,930
- CITADEL ADVISORS LLC added 3,963,609 shares (+42.1%) to their portfolio in Q1 2025, for an estimated $287,282,380
- MILLENNIUM MANAGEMENT LLC added 3,216,598 shares (+1409.8%) to their portfolio in Q1 2025, for an estimated $233,139,023
- MARSHALL WACE, LLP removed 2,782,748 shares (-47.9%) from their portfolio in Q1 2025, for an estimated $201,693,575
- JENNISON ASSOCIATES LLC added 2,576,383 shares (+34.3%) to their portfolio in Q1 2025, for an estimated $186,736,239
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Edwards Lifesciences Government Contracts
We have seen $28,402,790 of award payments to $EW over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- EXPRESS REPORT: HEART VALVES: $295,500
- EXPRESS REPORT: 2ND QTR FY25 TAVR HEART VALVES WITH CONSIGNMENT DELIVERY: $261,500
- HTM EV1000 PATIENT MONITORS: $246,000
- BILL PAY TRANSACTIONS: $238,000
- HEART VALVE: $238,000
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Edwards Lifesciences Analyst Ratings
Wall Street analysts have issued reports on $EW in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 07/25/2025
- Mizuho issued a "Outperform" rating on 07/25/2025
- RBC Capital issued a "Outperform" rating on 07/25/2025
- Piper Sandler issued a "Overweight" rating on 07/25/2025
- Wells Fargo issued a "Overweight" rating on 07/25/2025
- Barclays issued a "Overweight" rating on 07/25/2025
- Deutsche Bank issued a "Buy" rating on 07/25/2025
To track analyst ratings and price targets for Edwards Lifesciences, check out Quiver Quantitative's $EW forecast page.
Edwards Lifesciences Price Targets
Multiple analysts have issued price targets for $EW recently. We have seen 14 analysts offer price targets for $EW in the last 6 months, with a median target of $87.0.
Here are some recent targets:
- Larry Biegelsen from Wells Fargo set a target price of $84.0 on 07/25/2025
- Adam Maeder from Piper Sandler set a target price of $90.0 on 07/25/2025
- Anthony Petrone from Mizuho set a target price of $95.0 on 07/25/2025
- William Plovanic from Canaccord Genuity set a target price of $81.0 on 07/25/2025
- Matt Miksic from Barclays set a target price of $95.0 on 07/25/2025
- Rick Wise from Stifel set a target price of $95.0 on 07/25/2025
- Richard Newitter from Truist Securities set a target price of $82.0 on 07/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
